Shockwave therapy and EMTT work by triggering a biological healing response. That response runs through the same body that is dealing with everything else. When background biology is already working against tissue repair, a treatment that reliably helps one patient can underperform in another, with identical technique and equipment. Three factors come up often enough to understand: metabolic inflammation (often tied to diabetes and excess weight), autoimmune and rheumatic disease, and gut health. None of them make shockwave pointless. Each can change what "working" looks like and what needs to happen alongside treatment.
Shockwave works through the body's repair response
It's easy to think of ESWT (extracorporeal shockwave therapy) as something that physically breaks up scar tissue or "shakes loose" an adhesion. The pressure wave creates a controlled, low-grade injury signal that recruits the body's own repair machinery: fibroblasts, growth factors, and new blood vessel formation. Those remodel the area. The mechanical part is real, but the result depends on that cellular response showing up and doing its job.
A chronic condition that keeps the immune system or metabolism disrupted can change that response. The shockwave still fires the starting gun. What varies is how well the runners perform.
Diabetes and metabolic inflammation: what comes with the diagnosis
This factor has the most direct research behind it. The finding is more specific, and more useful, than "diabetics respond worse to shockwave."
A 2026 retrospective cohort study of 239 patients treated with focused ESWT for rotator cuff tendinopathy asked which clinical and metabolic factors predict a weaker response. Diabetes itself, along with high cholesterol and high blood pressure, did not come out as a significant independent predictor of a worse outcome. Body mass index did. Each one-point increase in BMI was associated with measurably less improvement in shoulder function scores. The authors tied this to the chronic low-grade inflammation and oxidative stress that come with excess adipose tissue, not to any single diagnosis on a chart.
So the more relevant question may be how much systemic inflammation is in the picture, more than whether someone has diabetes. A well-controlled diagnosis on paper can carry a very different inflammatory load than a poorly controlled one.
At the tissue level, diabetes also has its own mechanism, independent of body weight. Elevated blood sugar drives the buildup of advanced glycation end-products (AGEs). These compounds stiffen and cross-link collagen. Per a recent narrative review, they also directly suppress tendon cell proliferation, increase cell death, and disrupt the normal balance between building and breaking down connective tissue matrix. People with diabetes are estimated to be roughly four times more likely to develop tendon complications. The same research found that getting blood sugar back under control doesn't fully reverse tendon changes already in place. The damage is structural and persists after glucose is controlled.
None of this takes shockwave off the table for someone with diabetes. A 2025 systematic review and meta-analysis pooling 352 patients across seven studies found ESWT produced substantial, statistically robust pain reduction in diabetic patients treated for adhesive capsulitis (frozen shoulder). For this group, realistic expectations, closer attention to inflammation and metabolic health, and sometimes a longer course may matter more than for a metabolically healthy patient with the same injury.
Autoimmune and rheumatic disease: an immune system already acting on connective tissue
Rheumatoid arthritis, lupus, psoriatic arthritis, and similar conditions create a different kind of background noise. It is immunological, not metabolic. These conditions run on chronically elevated inflammatory signaling molecules, particularly TNF-alpha and IL-1 beta.
A recent review on tendon-bone healing lays out what these cytokines do to connective tissue, even outside autoimmune disease. They degrade the extracellular matrix and suppress the genes tendon cells need to maintain themselves. They also interfere with the normal handoff from the loose, disorganized collagen laid down early in healing (type III) to the stronger, organized collagen that should replace it (type I). When an autoimmune condition keeps baseline inflammatory signaling high, that degradative pressure runs in the background all the time, not only during the healing window after a treatment.
Medication is a separate, well-established factor. Many drugs used to control autoimmune and rheumatic disease, corticosteroids in particular, are independently associated with weaker, more rupture-prone tendon tissue. That isn't a reason to stop necessary medication. It is a reason to mention it during an evaluation, because it changes how aggressively and how quickly we use mechanical treatment like ESWT on an affected tendon.
Autoimmune disease doesn't rule shockwave out either. Timing matters more: working around flares instead of through them. Treatment usually needs to run alongside whatever is managing the underlying disease activity. A joint or tendon in a chronically inflamed environment is fighting an uphill battle that local treatment may not overcome on its own.
Gut health and "leaky gut": real biology, still an emerging picture
Here the popular language runs ahead of the clinical evidence, so precision matters. "Leaky gut" isn't a formal medical diagnosis. The underlying phenomenon, increased intestinal permeability, is real, measurable, and actively studied. Its connection to musculoskeletal healing is plausible but still developing.
Current research describes the mechanism this way. The gut lining is normally a tight barrier. Under physical stress, including injury itself and not only diet, that barrier can become more permeable. Bacterial fragments, particularly lipopolysaccharide from certain gut bacteria, can then slip into the bloodstream. One review notes intestinal permeability measurably increasing within 24 hours of a fracture in animal studies.
Those bacterial fragments trigger an immune receptor called TLR4, which drives a low-grade, body-wide inflammatory response. Acute inflammation is a normal, necessary part of healing. Sustained, excess inflammation impairs it. In the current preclinical literature, tendon and bone healing appear to slow under this kind of sustained inflammatory load. A leaky gut may therefore work against recovery from an injury elsewhere in the body.
The caveat: most of this evidence comes from animal models and mechanistic studies. Human clinical trials directly linking gut permeability to shockwave outcomes don't yet exist, and researchers are candid that translating the preclinical findings into patient care is still a work in progress. The practical side has more support. Diet quality, fiber intake that feeds beneficial gut bacteria, adequate hydration, and in some cases pre- or probiotics are reasonable, low-risk ways to support gut barrier integrity in general. That may remove one more variable working against tissue healing while the ESWT-specific research catches up.
What this means if you have one of these conditions
Someone with well-managed metabolic health, controlled autoimmune disease, and a reasonably healthy gut is working with a very different biological environment than someone dealing with all three, even if the MRI of the injured area looks identical. That doesn't rule out shockwave or EMTT. It means the whole picture belongs in the conversation before treatment starts.
A proper evaluation looks at more than the painful spot, and adhesion treatment is only one piece of a bigger plan. If shockwave or EMTT did less than you expected before, or you have a chronic condition and wonder whether treatment is worth trying, book a new patient exam.
